United Therapeutics Corp
UTHR
$517.71
-1.54%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease. It is a market leader in PAH, with a portfolio centered on the prostacyclin pathway, particularly treprostinil-based treatments like Tyvaso DPI. The current investor narrative is driven by positive Phase 3 data for Tyvaso in a new lung disease, setting up a major FDA filing and potential market expansion, while the stock has shown strong long-term gains but recent short-term volatility.…
UTHR
United Therapeutics Corp
$517.71
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating: Buy. United Therapeutics is a high-quality biotech with a strong balance sheet, robust profitability, and a clear catalyst in Tyvaso's label expansion, offering a favorable risk/reward at current levels. The consensus analyst rating is 'Buy' with an average target of $663.23, implying ~25.5% upside.
Supporting Evidence: UTHR's trailing P/E of 16.17x is a 27% discount to the biotech industry average of ~22x, providing a valuation cushion. Revenue has been stable around $780-800M per quarter, and the company maintains a net margin of 35.2% and free cash flow of $1.017B TTM. The PEG ratio of 1.16x suggests reasonable pricing relative to earnings growth. With a consensus EPS estimate of $59.25 for the current fiscal year, the forward P/E of 16.0x implies modest growth expectations that could be exceeded if Tyvaso's new indication gains approval.
Risks & Conditions: The primary risks are FDA decision on Tyvaso's new indication and potential revenue concentration. This Buy rating would be downgraded to Hold if the stock approaches the $663 average target without a clear approval catalyst, or if revenue growth fails to materialize. A Sell would be warranted if Tyvaso's expansion is rejected or delayed, causing the stock to break below $516 (low analyst target). Overall, UTHR appears undervalued relative to its profitability and balance sheet strength, but fairly valued relative to its current growth trajectory; the upside depends on the Tyvaso catalyst.
Sign up to view all
UTHR 12-Month Price Forecast
UTHR presents a balanced risk/reward with a clear upside catalyst in Tyvaso's label expansion. The stock's low P/E relative to peers and strong financials provide a margin of safety, while the analyst consensus points to significant upside. However, the recent price weakness and revenue stagnation warrant a medium confidence level. The stance would be upgraded to high confidence if Tyvaso receives FDA approval with a broad label, and downgraded to neutral if the approval is delayed or the stock approaches the average target without new catalysts.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $663.23 and implied upside of +28.1% versus the current price.
Average Target
$663.23
0 analysts
Implied Upside
+28.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$516 - $750
Analyst target range
The stock is covered by 13 analysts, with a consensus recommendation of 'Buy' (mean rating 1.6 on a 1-5 scale). The average target price is $663.23, implying approximately +25.5% upside from the current price of $528.47. The distribution leans bullish, with 8 buys, 4 holds, and 1 sell (implied). The target range spans from a low of $516.00 to a high of $750.00. The high target of $750.00 assumes successful FDA approval and commercial expansion of Tyvaso in a new indication, driving significant revenue growth. The low target of $516.00 reflects risks such as competitive pressure, pipeline setbacks, or slower-than-expected adoption. Recent ratings actions include a Wells Fargo upgrade from Equal Weight to Overweight in May 2026, and consistent Outperform ratings from RBC Capital. The wide spread between low and high targets ($234) indicates high uncertainty around the Tyvaso expansion opportunity, but the overall bullish consensus suggests analysts see more upside than downside.
Drowning in data?
Find the real signal!
Bulls vs Bears: UTHR Investment Factors
United Therapeutics presents a compelling risk/reward profile, balancing strong profitability, a fortress balance sheet, and a clear near-term catalyst (Tyvaso label expansion) against stagnant core revenue and high product concentration. The bull case is supported by a 25.5% analyst upside and a P/E discount to peers, while the bear case hinges on revenue stagnation and pipeline dependency. The single most important tension is whether Tyvaso's new indication will gain FDA approval and drive meaningful revenue growth; a positive outcome could propel the stock toward the $750 high target, while a failure could see it test the $516 low target. Currently, the evidence slightly favors the bull case given the strong financials and analyst optimism, but the stock's recent price weakness warrants caution.
Bullish
- Strong Profitability and Cash Flow: UTHR boasts a net margin of 35.2% and generated $1.017 billion in free cash flow over the trailing twelve months, indicating exceptional earnings quality and financial flexibility. This cash flow supports internal growth and shareholder returns without reliance on debt.
- Attractive Valuation vs. Peers: With a trailing P/E of 16.17x, UTHR trades at a 27% discount to the biotechnology industry average of ~22x. This discount may not fully reflect the potential upside from Tyvaso's new indication, offering a margin of safety.
- Analyst Consensus and Upside: The stock has a consensus 'Buy' rating with an average target price of $663.23, implying ~25.5% upside from the current price of $528.47. The high target of $750 suggests even greater potential if the Tyvaso expansion succeeds.
- Low Financial Risk: UTHR has a debt-to-equity ratio of just 0.0053 and a current ratio of 6.60, indicating a fortress balance sheet. This minimizes bankruptcy risk and allows the company to weather industry downturns or invest aggressively in growth.
Bearish
- Revenue Growth Stagnation: Q1 2026 revenue of $781.5M declined -1.62% YoY from $794.4M, and revenue has been flat around $780-800M for the past four quarters. This suggests the core PAH portfolio is mature with limited organic growth.
- High Concentration on Tyvaso: Tyvaso accounts for 58.5% of total revenue ($457.5M). Any setback in its label expansion, manufacturing, or competition could disproportionately impact the top line, making the stock highly sensitive to Tyvaso-specific news.
- Recent Price Momentum Weakness: The stock has declined -3.90% over the past month and -6.82% over the past three months, underperforming the S&P 500 by -4.68% and -10.32% respectively. This short-term weakness may signal fading investor enthusiasm.
- Limited Pipeline Beyond Tyvaso: UTHR's pipeline is heavily dependent on Tyvaso for future growth, with few other late-stage candidates. If the Tyvaso expansion fails or faces delays, the company lacks a clear growth driver, potentially capping upside.
UTHR Technical Analysis
The stock is in a sustained uptrend over the past year, with a 1-year price change of +72.47%. The current price of $528.47 sits at 72.5% of its 52-week range ($272.12 to $609.35), indicating it is closer to the highs but not overextended. This positioning suggests momentum is intact but with room for further upside before reaching resistance. Short-term momentum has decelerated, with a 1-month change of -3.90% and a 3-month change of -6.82%, diverging from the strong 1-year trend. This divergence could signal a temporary pullback or consolidation within a broader uptrend, rather than a reversal, given the stock's relative strength versus the S&P 500 (1-year relative strength of +56.00%). The 52-week high of $609.35 acts as key resistance; a breakout above this level would signal renewed bullish momentum and potential for further gains. The 52-week low of $272.12 provides strong support, and a breakdown below this level would be a bearish signal. With a beta of 0.58, the stock is significantly less volatile than the market, meaning it tends to move less than the S&P 500, which can be attractive for risk-averse investors.
Beta
0.58
0.58x market volatility
Max Drawdown
-13.3%
Largest decline past year
52-Week Range
$283-$609
Price range past year
Annual Return
+88.5%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -5.4% | +0.2% |
| 3m | -9.2% | +3.7% |
| 6m | +10.3% | +8.0% |
| 1y | +88.5% | +18.2% |
| ytd | +4.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue has been relatively stable but showed a slight decline in the most recent quarter. Q1 2026 revenue was $781.5 million, down -1.62% year-over-year from $794.4 million in Q1 2025. However, revenue has been in a tight range around $780-800 million over the past four quarters, indicating a mature product portfolio. Tyvaso is the primary growth driver, contributing $457.5 million in revenue (58.5% of total), while Remodulin and Orenitram add $126.6 million and $135.6 million, respectively. The company is highly profitable, with Q1 2026 net income of $274.9 million and a net margin of 35.2%. Gross margin remains strong at 82.9%, though slightly down from 88.4% in Q1 2025. Operating margin was 41.7% in Q1 2026, reflecting efficient cost management. The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.0053 and a current ratio of 6.60. Free cash flow (TTM) is $1.017 billion, providing ample liquidity for internal growth and shareholder returns. ROE is 18.8%, indicating efficient use of equity capital.
Quarterly Revenue
$781500000.0B
2026-03
Revenue YoY Growth
-1.6%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 16.17x, while the forward P/E is 16.00x, implying stable earnings expectations. The narrow gap between trailing and forward multiples suggests the market does not anticipate significant earnings growth or contraction in the near term. Compared to the biotechnology industry average P/E of approximately 22x (based on available data), UTHR trades at a 27% discount (16.17x vs. 22x). This discount may be justified by the company's mature growth profile and lack of a robust pipeline beyond Tyvaso, but it also highlights potential value if the new Tyvaso indication gains FDA approval. Historically, the trailing P/E has ranged from about 8.9x (Q1 2022) to 24.4x (Q2 2022). At 16.17x, the current P/E is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The PEG ratio of 1.16x indicates the stock is reasonably priced relative to its earnings growth rate.
PE
16.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UTHR's financial risk is minimal due to its near-zero debt (debt-to-equity of 0.0053) and strong liquidity (current ratio of 6.60). However, the company faces operational risk from revenue concentration: Tyvaso contributed 58.5% of Q1 2026 revenue, and any disruption in its supply chain, manufacturing, or competitive positioning could severely impact earnings. Additionally, the slight YoY revenue decline (-1.62%) in Q1 2026 suggests the core PAH market may be maturing, limiting top-line growth without new indications. The net margin of 35.2% is robust, but any pricing pressure or increased R&D spending for pipeline expansion could compress margins.
Market & Competitive Risks: UTHR trades at a P/E of 16.17x, a discount to the biotech industry average of 22x, which could narrow if the Tyvaso expansion fails, leading to valuation compression. The stock's beta of 0.58 indicates lower market correlation, but it is still exposed to sector-specific headwinds such as FDA regulatory delays, competitor advancements in PAH (e.g., oral prostacyclin therapies), and potential drug pricing reforms. The recent positive Phase 3 data for Tyvaso has already been partially priced in, and any negative regulatory surprise could trigger a sharp selloff. The wide analyst target range ($516-$750) underscores high uncertainty around the Tyvaso opportunity.
Worst-Case Scenario: The most damaging scenario would be an FDA rejection or significant delay for Tyvaso's new indication, combined with continued revenue stagnation in the core PAH portfolio. In this case, the stock could fall to its 52-week low of $272.12, representing a -48.5% decline from the current price of $528.47. This would imply a P/E compression to around 8.3x, reflecting a loss of growth premium and potential earnings downgrades. The low analyst target of $516 already accounts for some downside, but a complete failure of the Tyvaso expansion could push the stock below that level.
FAQ
The key risks are: 1) Tyvaso concentration risk, as it accounts for 58.5% of revenue; any setback in its label expansion could significantly impact earnings. 2) Revenue stagnation risk, with Q1 2026 revenue declining -1.62% YoY, indicating limited organic growth in the core PAH market. 3) Regulatory risk, as the Tyvaso new indication is subject to FDA approval; a rejection could send the stock to the 52-week low of $272.12 (-48.5% downside). 4) Competitive risk from other PAH therapies, including oral prostacyclin analogs that could erode Tyvaso's market share. The most severe risk is the binary outcome of the FDA decision, which could lead to a -48.5% loss in a worst-case scenario.
The 12-month forecast for UTHR is scenario-dependent. In the bull case (30% probability), Tyvaso's new indication is approved, driving the stock to $663-$750 (25-42% upside). In the base case (50% probability), the stock trades around the average target of $663 (25.5% upside) with modest growth. In the bear case (20% probability), FDA rejection leads to a decline to $272-$516 (-48.5% to -2.4% downside). The most likely scenario is the base case, assuming Tyvaso approval with moderate commercial uptake. The key assumption is that the FDA approves Tyvaso for the new indication, which would validate the growth thesis and support the current valuation.
Based on a trailing P/E of 16.17x, UTHR is undervalued relative to the biotechnology industry average of ~22x, representing a 27% discount. This discount may be justified by the company's mature growth profile and lack of a robust pipeline beyond Tyvaso. However, compared to its own historical P/E range of 8.9x to 24.4x, the current multiple is near the middle, suggesting fair value relative to its own history. The PEG ratio of 1.16x indicates the stock is reasonably priced relative to its earnings growth rate. Overall, UTHR appears undervalued on a peer comparison basis but fairly valued on an absolute basis, with the potential for multiple expansion if the Tyvaso catalyst materializes.
UTHR appears to be a good buy for investors with a moderate risk tolerance and a 12-month horizon, given its attractive valuation (P/E 16.17x vs. industry 22x), strong profitability (net margin 35.2%), and a clear catalyst in Tyvaso's label expansion. The analyst consensus 'Buy' with 25.5% upside to the average target of $663.23 supports a favorable risk/reward. However, the stock is not without risks: revenue has been flat, and the Tyvaso expansion is binary. For long-term investors, the low debt and high free cash flow provide a safety net, but the stock's performance hinges on FDA approval. It is a good buy for those who believe in Tyvaso's potential and can tolerate short-term volatility.
UTHR is suitable for both short-term and long-term investment, but with different risk profiles. For short-term traders (6-12 months), the stock offers a binary catalyst in the Tyvaso FDA decision, which could drive significant price movement. The low beta of 0.58 means less volatility than the market, but the event risk is high. For long-term investors (3-5 years), UTHR's strong balance sheet, high free cash flow, and dominant position in PAH provide a stable foundation, but the lack of a diversified pipeline beyond Tyvaso limits long-term growth visibility. A minimum holding period of 12 months is recommended to capture the Tyvaso catalyst, after which the thesis should be reassessed based on the outcome.
